Agenus Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| AGEN | CHRS | ADAG | PYXS | ATORX.ST | HURA | |
|---|---|---|---|---|---|---|
| Market cap | 314.78M | 131.36M | 161.82M | 198.30M | 38.18M | 109.61M |
| P/E (TTM) | 2.8 | — | — | — | — | — |
| Forward P/E | -63.4 | -1.3 | -4.3 | -1.5 | -0.1 | -2.8 |
| Price/book | -1.5 | 2.2 | 1.8 | 9.2 | 0.3 | 6.0 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | +81.51% | −42.95% | +49.69% | −58.91% | −99.44% | −29.80% |
| Today | +4.50% | +5.54% | +2.55% | +1.22% | 0.00% | +3.93% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All AGEN news ›Agenus to Participate in Rodman & Renshaw Virtual Fireside Chat
BioSpace LEXINGTON, Mass.--(BUSINESS WIRE)--$AGEN #IO--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that Robin Taylor, Chief Commercial Officer, and Zack Armen, Vice President of Corporate Developm
Agenus Announces Nature Medicine Publication of Multicenter UNICORN Phase 2 Trial Demonstrating Deep Responses with Neoadjuvant BOT+BAL in Resectable Colon Cancer
Among the 14 patients with pMMR/MSS colon cancer treated with BOT+BAL, 36% achieved a major pathologic response (MPR), defined as 10% or less viable tumor remaining at surgery, and 29% achieved a pathologic complete response (pCR), meaning…
Phase 3 ROBBIN Trial Targets Q1 2027 Opening in MSS Colon Cancer – Agenus
“Preparations for Phase 3 ROBBIN are moving forward. Following ESMO, our medical team traveled to São Paulo, Brazil, where a packed room of investigators and trial site teams came together to prepare for the study’s planned opening in Q1…
Critical Contrast: Agenus (NASDAQ:AGEN) versus AbCellera Biologics (NASDAQ:ABCL)
Posted by Kim Johansen on Nov 1st, 2026 Agenus (NASDAQ:AGEN – Get Free Report) and AbCellera Biologics (NASDAQ:ABCL – Get Free Report) are both healthcare companies, but which is the superior investment? We will contrast the two businesses…
Agenus reports response rate in colon cancer trial
Agenus colon cancer trial showed 72% complete responses before surgery. SeventyFour/iStock via Getty Images Agenus (AGEN) reported that 72% of patients with locally advanced colon cancer had no detectable cancer remaining at surgery after…
Agenus Reports 72% of Patients with Locally Advanced dMMR Colon Cancer Had No Cancer Remaining at Surgery Following Six Weeks of BOT+BAL in Phase 2 NEOASIS Study at ESMO 2026
The cohort met its primary endpoint, with 83% of 18 patients achieving a major pathologic response (MPR), defined as 10% or less viable tumor remaining at surgery, and 72% achieving a pathologic complete response (pCR), with no cancer…
Bold Science, Big Questions, a Defining Moment for Cancer Immunotherapy – Agenus
Agenus shared on LinkedIn: “Bold Science. Big Questions. A Defining Moment for Cancer Immunotherapy. On Saturday, October 24, at 6:15 PM in Madrid, Jennifer S. Buell joins global oncology leaders, including Prof. Jean-Yves Blay, Dr. Julie…
Armenia Becomes First Country to Approve Agenus’ BOT+BAL for MSS Metastatic Colorectal Cancer
Armenia has become the first country in the world to grant marketing authorizations for Agenus’ botensilimab and balstilimab (BOT+BAL), marking the first approvals of either medicine globally. The authorizations cover their combined use in…
Agenus to Participate in Chardan’s 10th Annual Healthcare Investor Conference
BioSpace LEXINGTON, Mass.--(BUSINESS WIRE)--$AGEN #Botensilimab--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that Zack Armen, Head of Corporate Development and Investor Relations, wi
Vivani Medical Announces Participation in Upcoming Investor Conferences
October 12, 2026 07:00 ET | Source: Vivani Medical, Inc. Vivani Medical, Inc. ALAMEDA, Calif., Oct. 12, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (Nasdaq: VANI) ("Vivani" or the "Company"), a clinical-stage biopharmaceutical company…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- themarketsdaily.com4
- biospace.com2
- globenewswire.com1
- stocktitan.net1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 8 articles, not a forecast.